|
504 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1357 Trials |
|
122306 News |
|
| «12...1011121314151617181920...15251526» |
- | doxorubicin hydrochloride / Generic mfg.
Journal: Intravenous Thrombolysis for Pediatric Ischemic Stroke Secondary to Cancer Therapy-related Cardiac Dysfunction: A Case Report. (Pubmed Central) - May 30, 2024
He originally developed Ewing sarcoma and was treated with high-dose chemotherapy including doxorubicin...The patient did not exhibit any neurological deficits during discharge. Reperfusion therapy for pediatric patients has not yet been established; however, it may be effective for CES secondary to CTRCD.
- | Journal: Hypopharyngeal liposarcoma:a case report (Pubmed Central) - May 30, 2024
Reperfusion therapy for pediatric patients has not yet been established; however, it may be effective for CES secondary to CTRCD. No abstract available
- | Journal, Stroma: Submucosal tunneling endoscopic resection technique with intermuscular dissection for a rectal gastrointestinal stromal tumor. (Pubmed Central) - May 30, 2024
No abstract available No abstract available
- | cisplatin / Generic mfg.
Journal: Vibrational microspectroscopy as a tool to unveil new chemotherapeutic strategies against osteosarcoma. (Pubmed Central) - May 30, 2024
The main changes were observed for the B-DNA native conformation to either Z-DNA (higher in the presence of polynuclear complexes) or A-DNA (preferably after cisplatin exposure). Additionally, a higher effect upon variation in proteins content was detected in drug combination when compared to single drug administration proving the efficacy of the EURAMOS-1 protocol with the new drugs tested.
- | Preclinical, Journal: E2F transcription factor-1 modulates expression of glutamine metabolic genes in mouse embryonic fibroblasts and uterine sarcoma cells. (Pubmed Central) - May 30, 2024
CRISPR/Cas9 knockout of E2F1 in the uterine sarcoma cell line SK-UT-1 confirmed elevated glutamine metabolic gene expression, increased proliferation and increased MYC binding to glutamine-related promoters upon E2F1 loss. Together, our data suggest a crucial role of E2F1 in energy metabolism and metabolic adaptation in uterine sarcoma cells.
- | bezuclastinib (PLX9486) / Cogent Biosci
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST (clinicaltrials.gov) - May 29, 2024
P2, N=40, Not yet recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Together, our data suggest a crucial role of E2F1 in energy metabolism and metabolic adaptation in uterine sarcoma cells. Trial completion date: Mar 2027 --> Jun 2027 | Trial primary completion date: Mar 2026 --> Jun 2026
- INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY () - May 29, 2024 - Abstract #EULAR2024EULAR_4000;
It appears that the risk of relapse of inflammation in patients receiving bDMARDs is high. Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment.
- Olumiant (baricitinib) / Eli Lilly, Rinvoq (upadacitinib) / AbbVie
LONG-TERM SAFETY EVALUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TNFi VS JAKi DRUGS IN CLINICAL PRACTICE: RESULTS FROM A LOCAL REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3555;
Between both groups, no differences were detected in conventional risk factors, appearance of thrombosis or neoplasia. 2.
- | Biomarker, Journal: CORR Insights (Pubmed Central) - May 29, 2024
2. No abstract available
- | Journal: CORR Insights (Pubmed Central) - May 29, 2024
No abstract available No abstract available
- | Vitrakvi (larotrectinib) / Bayer
Journal, Real-world evidence, Real-world: Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology. (Pubmed Central) - May 29, 2024
This real-world study confirms favorable agnostic tumor OR rates to larotrectinib in children with NTRK-fused tumors. Better coordination to facilitate access to medication remains a challenge, particularly in middle-income countries like Brazil.
- | Journal: Clinical implications and molecular features of extracellular matrix networks in soft tissue sarcomas. (Pubmed Central) - May 29, 2024
Better coordination to facilitate access to medication remains a challenge, particularly in middle-income countries like Brazil. STS comprise heterogeneous ECM signalling networks and matrix-specific features have utility for risk stratification and therapy selection which could in future guide precision medicine in these rare cancers.
- | Journal: Bullous Kaposi Sarcoma: An Uncommon Blistering Variant in an HIV-Negative Patient. (Pubmed Central) - May 29, 2024
STS comprise heterogeneous ECM signalling networks and matrix-specific features have utility for risk stratification and therapy selection which could in future guide precision medicine in these rare cancers. No abstract available
- | zoledronic acid / Generic mfg.
Preclinical, Journal: Payload-delivering engineered ?? T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma. (Pubmed Central) - May 29, 2024
Together, the data identify stIL15-OPS-?? T cells as a candidate allogeneic cell therapy platform combining direct cytolysis with bystander activation to promote tumor control.
- || cisplatin / Generic mfg., methotrexate / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical, Retrospective data, Journal: Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis. (Pubmed Central) - May 29, 2024
T cells as a candidate allogeneic cell therapy platform combining direct cytolysis with bystander activation to promote tumor control. The present meta-analysis showed that the MAP regimen remains preferable in treating osteosarcoma patients despite no significant outcome compared to the other regimens considering the less frequent AE in the MAP regimen.
- || Review, Journal, Surgery: What is the Optimal Treatment Strategy after Sarcoma R2 Surgery? (Pubmed Central) - May 29, 2024
Following non-radical treatment, patients with limb and trunk wall sarcomas and retroperitoneal sarcomas should also undergo increased oncological surveillance. Given the potential issues that may emerge in such clinical situations, it is crucial to up-date the current guidelines to enhance the long-term prognosis of these patients.
- | Preclinical, Journal: Preliminary evaluation of the toxicological, antioxidant and antitumor activities promoted by the compounds 2,4-dihydroxy-benzylidene-thiosemicarbazones an in silico, in vitro and in vivo study. (Pubmed Central) - May 29, 2024
Finally, all compounds showed promising antitumor activity against different cell lines, especially MCF-7 and DU145 lines, in addition, they inhibited the growth of sarcoma 180 at concentrations lower than 50 mg/kg. These results showed that the evaluated compounds can be considered as potential antitumor agents.
- | Journal: Incidental diagnosis of cardiac fibroma in an infant with acute viral bronchiolitis. (Pubmed Central) - May 29, 2024
When tumors are unresectable, heart transplantation should be indicated. It is essential to have detailed characterization of the cardiac mass to establish the most appropriate therapeutic approach for each patient.
- | Journal: Aggressive EWSR1::POU2AF3(COLCA2) spindle/round cell sarcoma of the sinonasal tract. (Pubmed Central) - May 29, 2024
It is essential to have detailed characterization of the cardiac mass to establish the most appropriate therapeutic approach for each patient. No abstract available
- | Journal: Gene Transfection Efficiency Improvement with Lipid Conjugated Cationic Carbon Dots. (Pubmed Central) - May 29, 2024
Furthermore, APCDs-0.5OA show prominent siRNA transfection efficiency, which is proven by the significantly downregulated expression of FANCA and FANCD2 proteins upon delivery of FANCA siRNA and FANCD2 siRNA into U2OS cells. In conclusion, our work demonstrates that conjugation of CCDs with a lipid structure such as OA significantly improves the gene transfection efficiency, providing a new idea about the designation of nonviral carriers in gene delivery systems.
- | gemcitabine / Generic mfg.
Journal: Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis. (Pubmed Central) - May 29, 2024
In this study, a novel formulation was developed using natural biological H-ferritin (HFn) encapsulating the photosensitizer IR-780 and the chemotherapy drug gemcitabine (Gem) for OS-specific targeted therapy (HFn@Gem/IR-780 NPs)...Importantly, HFn@Gem/IR-780 NPs demonstrated excellent safety profile with significantly decreased drug exposure to normal organs, indicating its potential for reducing systemic toxicity. Thus, utilizing HFn as a vehicle to encapsulate highly effective antitumor drugs provides a promising approach for the treatment of OS metastasis and relapse.
- || imatinib / Generic mfg.
Clinical data, Retrospective data, Journal, Stroma: Clinical outcomes of endoscopic resection for the treatment of intermediate- or high-risk gastric small gastrointestinal stromal tumors: a multicenter retrospective study. (Pubmed Central) - May 29, 2024
ER for intermediate- or high-risk gastric small GISTs is a feasible and safe method, which allows for a wait-and-see approach before determining the necessity for imatinib adjuvant or surgical treatment. This approach to g-GISTs does require that patients undergo close follow-up.
- | Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion date: Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) - May 29, 2024
P2, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Trial completion, Phase classification, Metastases: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 29, 2024
P2, N=126, Completed, Sponsor: ImmunityBio, Inc.
This approach to g-GISTs does require that patients undergo close follow-up. Unknown status --> Completed | Phase classification: P2b --> P2
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion, Enrollment change: Pulmonary sarcomatoid_MEDI4736+Treme (clinicaltrials.gov) - May 29, 2024
P2, N=32, Completed, Sponsor: Seoul National University Hospital
Unknown status --> Completed | Phase classification: P2b --> P2 Unknown status --> Completed | N=18 --> 32
- ||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment change, Combination therapy, Metastases: Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (clinicaltrials.gov) - May 29, 2024
P2/3, N=360, Recruiting, Sponsor: PharmaMar
Unknown status --> Completed | N=18 --> 32 N=240 --> 360
- | Journal: Hypercoagulability based on thromboelastography is common in dogs undergoing adrenalectomy. (Pubmed Central) - May 28, 2024
N=240 --> 360 The present report describes for the first time TEG findings for dogs undergoing adrenalectomy and suggests that the majority of dogs with adrenal neoplasia are hypercoagulable based on TEG results.
- | Retrospective data, Journal: Evaluation of cranial nerve involvement in chordomas and chondrosarcomas: a retrospective imaging study. (Pubmed Central) - May 28, 2024
The incidence of CNI and off-midline location in chondrosarcomas was significantly higher than that in chordomas. CNI, tumor location, and the mean ADC can help distinguish between these entities.
- || Clinical, Journal: Survival outcomes of patients with brain metastasis of osteosarcoma can be improved by aggressive multi-disciplinary interventions including chemotherapy. (Pubmed Central) - May 28, 2024
Multivariate analysis showed that chemotherapy was effective as surgery and radiotherapy for the treatment of BMO. Our findings emphasize the importance of regular neuroimaging and early aggressive multi-disciplinary interventions including surgical resection, postoperative radiotherapy and chemotherapy.
- || Review, Journal: Current management of familial adenomatous polyposis. (Pubmed Central) - May 28, 2024
FAP management requires a multidisciplinary and personalized approach. Integrating genetic advances, innovative surveillance techniques, and emerging therapeutic modalities will contribute to improving outcomes and quality of life for FAP individuals.
- | Journal: Laryngeal carcinosarcoma (Pubmed Central) - May 28, 2024
A clinical case of a rare malignant tumor of the larynx, carcinosarcoma, is described. The features of the clinical picture, diagnostic instrumental and morphological are presented.
- | Journal: Primary pelvic soft tissue sarcomas (PELVISARC): outcomes from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). (Pubmed Central) - May 28, 2024
The features of the clinical picture, diagnostic instrumental and morphological are presented. No abstract available
- | Journal: Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study. (Pubmed Central) - May 28, 2024
One canine mammary adenocarcinoma cell line and one mammary adenoma cell line showed significantly decreased viability after treatment, whereas the non-neoplastic cell line was resistant. We conclude that the reengineered anthrax toxin may be considered a targeted therapy for canine mammary neoplasms while preserving normal canine mammary epithelial cells.
- | Journal: Ultrasonographic and CT-scan findings of splenic active chylous effusion and postlymphangiography enhancement in a cat with chylothorax associated with splenic angiosarcoma. (Pubmed Central) - May 28, 2024
This case report highlights the utility of advanced thoracic and abdominal imaging, notably CT-lymphangiography, in the diagnostic evaluation of chylothorax in cats. The identification of a splenic mass encased in chylous effusion should prompt a proactive case management strategy.
- | cisplatin / Generic mfg.
Journal: Endowing Pt(IV) with Perfluorocarbon Chains and Human Serum Albumin Encapsulation for Highly Effective Antitumor Chemoimmunotherapy. (Pubmed Central) - May 28, 2024
Herein, the axial functionalization of the Pt(II) complex cisplatin with perfluorocarbon chains into ICD-inducing Pt(IV) prodrugs is reported...In vivo tumor vaccine analysis also demonstrated the ability of Pt(IV) to be an ideal ICD inducer. Overall, this study reports on axially perfluorocarbon chain-modified Pt(IV) complexes for ICD induction and chemoimmunotherapy in osteosarcoma.
- | Journal: A GAD1 inhibitor suppresses osteosarcoma growth through the Wnt/?-catenin signaling pathway. (Pubmed Central) - May 28, 2024
Regarding the mechanism, 3-MPA inhibited ?-catenin and cyclin D1 in OS cells, thereby inactivating the Wnt/?-catenin pathway. OS displays increased expression of the GABAergic neuronal marker GAD1, and 3-MPA significantly reduces OS growth by inhibiting the Wnt/?-catenin pathway.
- | Qinlock (ripretinib) / Deciphera
New trial, Stroma, Metastases: The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients With Advanced GISTs (clinicaltrials.gov) - May 28, 2024
P=N/A, N=60, Not yet recruiting, Sponsor: First Affiliated Hospital, Sun Yat-Sen University
- | Biomarker, Journal, Metastases: A novel nomogram and prognostic factor for metastatic soft tissue sarcoma survival. (Pubmed Central) - May 28, 2024
This study marked the inaugural effort in constructing predictive survival nomograms mSTS patients in the era of immune checkpoint inhibitors. The robustly constructed nomograms, alongside actual outcomes, offered valuable insights to inform follow-up management strategies.
- | gentamicin sulfate / Generic mfg.
Journal: Microwave-assisted synthesis of novel Ti/BTB-MOFs as porous anticancer and antibacterial agents. (Pubmed Central) - May 28, 2024
The antimicrobial activity of Ti/BTB-MOF was higher than that of penicillin and gentamicin. Therefore, the synthesized Ti/BTB-MOF could be introduced as a suitable bioactive candidate.
- | Ayvakit (avapritinib) / Blueprint Medicines
Journal: Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1. (Pubmed Central) - May 28, 2024
Avapritinib has the potential to cause intestinal DDIs via the inhibition of UGT1A1. Additional attention should be paid when avapritinib is coadministered with UGT1A1 substrates.
- | Lumakras (sotorasib) / Amgen
Phase classification, Combination therapy, Monotherapy, Metastases: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - May 28, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Additional attention should be paid when avapritinib is coadministered with UGT1A1 substrates. Phase classification: P1/2 --> P1
- | fulvestrant / Generic mfg.
Trial completion, Enrollment change, Metastases: FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (clinicaltrials.gov) - May 28, 2024
P2, N=17, Completed, Sponsor: Frederic Amant
Phase classification: P1/2 --> P1 Recruiting --> Completed | N=200 --> 17
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes (clinicaltrials.gov) - May 27, 2024
P2, N=56, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=200 --> 17 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- || Review, Journal: From oncogenes to tumor suppressors: The dual role of ncRNAs in fibrosarcoma. (Pubmed Central) - May 27, 2024
Targeting ncRNAs emerges as a promising strategy for fibrosarcoma therapy, offering hope to overcome the shortcomings of existing treatments. Further investigation is needed to clarify specific ncRNAs' roles in fibrosarcoma and to develop ncRNA-based therapies, highlighting the significance of ncRNAs in improving patient outcomes in this challenging cancer.
- | doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study. (Pubmed Central) - May 27, 2024
Further investigation is needed to clarify specific ncRNAs' roles in fibrosarcoma and to develop ncRNA-based therapies, highlighting the significance of ncRNAs in improving patient outcomes in this challenging cancer. The pharmacokinetic profile for doxorubicin in the investigated tissues is very similar when comparing bolus and 6
- || Biomarker, Review, Journal: Establishing biomarkers for soft tissue sarcomas. (Pubmed Central) - May 27, 2024
Currently, defining prognostic markers in soft tissue sarcomas remains challenging. More studies are required, especially to personalize treatment through advanced genetic profiling and analysis using individual tumor and patient characteristics.
- | Journal: Localized anaplastic lymphoma kinase-positive histiocytosis in a cerebellar hemisphere with long-term treatment: illustrative case. (Pubmed Central) - May 27, 2024
Although the prognosis of ALK-H is generally good according to prior cases, the authors' case required long-term conventional chemotherapy, suggesting the tumor displayed aggressive characteristics. Early administration of ALK inhibitors may be necessary.
- || Clinical, Review, Journal: A Systemic Review of Primary Malignant Long Bone Tumors in Children and Adolescents. (Pubmed Central) - May 27, 2024
Although focus of literature is more on the two most common tumours. However, rare tumours should be considered as they can mimic these common tumors.
- | Journal, Stroma: Multimode ultrasound imaging of an anal canal gastrointestinal stromal tumour (GIST). (Pubmed Central) - May 27, 2024
In the limited reports of anal canal GISTs, no other lesions have been correctly diagnosed preoperatively or displayed in detail on imaging. The multilayer structure of the anal sphincter and these lesions can be clearly displayed by a variety of ultrasound imaging methods, which are nonradiative, low-cost and easily accessible.
- | Journal: CD34/S100 protein-positive, NTRK1-rearranged infantile fibrosarcoma-like tumors in genitourinary system: two cases expanding the clinicopathologic spectrum and illustrating the diagnostic dilemma. (Pubmed Central) - May 27, 2024
Limited follow-up showed no tumor recurrences or metastases. We expand the clinicopathologic spectrum of IFS-like tumors harboring alternative NTRK1 fusions.